Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02913924 · ClinicalTrials.gov registry record · Phase 2
Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT02913924 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 68 participants.
The verdict
NCT02913924, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The proposed protocol is a double-blind, placebo-controlled inpatient and outpatient study,looking at the clinical treatment of cannabis use disorder. The treatment study is a total of 12 weeks. There will be two options offered to participants for week 1 of the treatment study. 1) Patient will go inpatient for 5 nights and after discharge from the inpatient phase will complete the 11-weeks of outpatient treatment or 2) patients who cannot complete the inpatient phase due to work or other obligations will complete the treatment 12-week study outpatient. 80 patients seeking treatment for cannabis use disorder will be enrolled into either the inpatient/outpatient or only outpatient study. This combined design will provide a comprehensive understanding of clonazepam's effects on individuals with cannabis use disorder across a range of outcome measures while also testing the medication's ability to prevent relapse in cannabis-abstinent patients.
Interventions
- DRUG Placebo
- DRUG Clonazepam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2016-12 |
| Est. Completion | 2020-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02913924
The ClinicalTrials.gov registry entry for NCT02913924 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02913924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02913924 about?
NCT02913924 is a clinical study titled "Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients". The proposed protocol is a double-blind, placebo-controlled inpatient and outpatient study,looking at the clinical treatment of cannabis use disorder. The treatment study is a total of 12 weeks. There will be two options offered to participants for week 1 of the treatment study. 1) Patient will go ...
What is the current status of trial NCT02913924?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2016-12. Estimated completion is 2020-06.
What interventions are being tested in trial NCT02913924?
The interventions under investigation include: Placebo (DRUG), Clonazepam (DRUG).
Who is sponsoring clinical trial NCT02913924?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.